Company: SNPS
Filing Date: 2025-03-05
Form Type: 424B5
Source: 0001140361-25-007235
Chunk: 22

Company: SYNOPSYS INC
Filing Date: 2025-03-05
Form: 424B5
Chunk 22
---
 the notes will be issued contains covenants restricting our ability, subject to certain exceptions, to incur debt secured by liens, to enter into sale and leaseback transactions or to merge or consolidate with another entity or sell substantially all of our assets to another person. See “Description of Notes—Covenants.”

S-9

#### TABLE OF CONTENTS

#### Minimum Denominations
The notes of each series will be issued and may be transferred only in minimum denominations of $2,000 and in integral multiples of $1,000 in excess thereof.

#### Form
The notes of each series will be issued in the form of one or more fully registered global notes without interest coupons which will be deposited with, or on behalf of, The Depository Trust Company (“DTC”), New York, New York, and registered in the name of Cede & Co., as nominee of DTC, for the accounts of participants in DTC. Unless and until exchanged, in whole or in part, for notes in definitive registered form, a global note may not be transferred except in the limited circumstances described under “Description of Notes—Book-Entry; Delivery and Form; Global Note.” Notes in certificated form will not be issued or exchanged for interests in global securities.

#### Use of Proceeds
We estimate that the net proceeds to us from this offering will be approximately $9,912,975,000, after deducting the underwriting discounts and estimated offering expenses payable by us. Absent a Special Mandatory Redemption, we intend to use the net proceeds from this offering, as well as our cash on hand, and borrowings under the Term Loan Credit Agreement and the Bridge Commitment, if applicable, to fund part of the cash portion of the merger consideration for the Ansys Merger, to pay related transaction fees and expenses and to repay Ansys’ outstanding indebtedness. Pending such uses, the net proceeds from this offering shall be invested in marketable securities. In the event of a Special Mandatory Redemption, the proceeds of the 2035 notes and 2055 notes will be used for general corporate purposes, which may include repayment of outstanding indebtedness. See “Use of Proceeds” in this prospectus supplement. This offering is not conditioned upon the completion of the Ansys Merger, which, if completed, will occur subsequent to the closing of this offering. However, if the Ansys Merger is not consummated by the Special Mandatory Redemption End Date or Synopsys otherwise determines not to pursue the consumm